Thermo Fisher Scientific (TMO) Stock
Global leader in laboratory instruments and consumables. Here's the price, business snapshot, and what's worth knowing about Thermo Fisher Scientific in August 2026.
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It’s Moving
TMO holds analyst support as investors lean on a gradual recovery story
- Analysts continue to view Thermo Fisher as a Buy, with broad coverage still clustered around a positive outlook, which suggests confidence in the company’s earnings power and resilient demand profile rather than a short-term trading call.
- Recent analyst targets still point to meaningful upside from the current share price, reinforcing the market’s view that TMO can keep compounding even without a near-term catalyst, but the range of estimates shows opinions remain varied.
- There were no major company-specific earnings or headline events in the last week, so the stock’s move is being shaped more by the broader life-sciences tools backdrop and investor expectations for a steadier demand recovery.
TMO holds analyst support as investors lean on a gradual recovery story
- Analysts continue to view Thermo Fisher as a Buy, with broad coverage still clustered around a positive outlook, which suggests confidence in the company’s earnings power and resilient demand profile rather than a short-term trading call.
- Recent analyst targets still point to meaningful upside from the current share price, reinforcing the market’s view that TMO can keep compounding even without a near-term catalyst, but the range of estimates shows opinions remain varied.
- There were no major company-specific earnings or headline events in the last week, so the stock’s move is being shaped more by the broader life-sciences tools backdrop and investor expectations for a steadier demand recovery.
When is the next earnings date for Thermo Fisher Scientific (TMO)?
Thermo Fisher Scientific (TMO) is expected to report its next earnings on July 23, 2026, based on the current consensus calendar, though some platforms still show an estimated window around that date. The report will cover Q2 2026 results. If the date is revised, it is typically adjusted closer to the company’s formal announcement.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Thermo Fisher Scientific's stock with a target price of $634.23, indicating potential growth.
Financial Health
Thermo Fisher Scientific is performing well with strong revenue, cash flow, and profit margins.
Dividend
Thermo Fisher Scientific has a low dividend yield of 0.31%, making it less attractive for dividend-seeking investors. If you invested $1000 you would be paid $3.10 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring TMO
mRNA Vaccines: Could Non-COVID Markets Drive Growth?
The FDA has granted its first-ever approval for an mRNA seasonal flu vaccine, moving the groundbreaking technology beyond its pandemic origins. This regulatory milestone creates compelling investment opportunities across innovative biotechnology firms and the specialized supply chains that support them.
Published: 7 August 2026
Explore BasketFood Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Published: 15 February 2026
Explore BasketFood Safety Investing: The Next Chapter Unfolds
Recent recalls of baby formula by Danone and other major brands, traced back to a single contaminated ingredient supplier, have exposed significant risks in the global supply chain. This situation creates a potential investment opportunity in companies focused on food safety, testing, and alternative brands with more secure sourcing.
Published: 24 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketLife Sciences Brazil | Clinical Trial Stock Exposure
Brazil's expanding role in global medical research may increase local access to cutting-edge treatments and stimulate economic growth. This basket provides exposure to the theme through US and EU-listed companies that supply critical services and infrastructure for clinical trials in the region.
Published: 3 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: 23 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
